Targeting fibroblast activation protein in rheumatoid arthritis: from molecular imaging to precision therapeutics
Frontiers in Immunology · 18.06.2025 · 16
DOI: 10.3389/fimmu.2025.1616618 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 18.06.2025. Verfasst von Yupeng Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Practice, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Serine Endopeptidases, Molecular Imaging, Gelatinases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rheumatoid arthritis (RA), a chronic inflammatory disorder characterized by synovitis and joint destruction, remains a global health challenge. Activated fibroblast-like synoviocytes (FLS), which play a crucial role in the progression of RA, demonstrate tumor-like invasiveness and secrete inflammatory mediators. Fibroblast activation protein (FAP), a type II transmembrane serine protease, has been extensively studied in oncology for decades and has yielded significant clinical benefits. FAP is highly expressed in tumor-associated fibroblasts and plays a pivotal role in tumor growth, dissemination, and immune escape. In cancer imaging, small-molecule FAP inhibitor (FAPI) PET/CT has demonstrated superior sensitivity for detecting primary tumors and metastases. Additionally, FAP-targeted radionuclide therapy has emerged as a promising strategy for delivering precise radiation to tumors, while sparing healthy tissues. Beyond oncology, research on FAP in non-malignant diseases is rapidly advancing. In RA, FAP is overexpressed in RA-FLS but scarce in normal tissues. Thus, FAPI PET/CT can accurately visualize synovitis and monitor the treatment response in patients with RA. Similarly, FAP imaging is used to assess extra-articular manifestations, such as interstitial lung disease and cardiac fibrosis, by mapping fibroblast activity, offering a non-invasive tool. Moreover, emerging therapies, such as FAP-targeted photodynamic therapy, selectively eliminate pathogenic cells in RA models, highlighting their therapeutic potential. This review highlights the advances in FAP-targeted imaging for RA, specifically focusing on FAP as a key biomarker for diagnosis, disease evaluation, and potential therapeutic use in RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Practice, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zitieren
APA
Huang, Y., Wu, Y., Liu, H., Chen, Y., Xie, Q., & Yin, G. (2025). Targeting fibroblast activation protein in rheumatoid arthritis: from molecular imaging to precision therapeutics. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1616618
Vancouver
Huang Y, Wu Y, Liu H, Chen Y, Xie Q, Yin G. Targeting fibroblast activation protein in rheumatoid arthritis: from molecular imaging to precision therapeutics. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1616618
BibTeX
@article{Huang2025,
author = {Huang, Yupeng and Wu, Yang and Liu, Huan and Chen, Yuehong and Xie, Qibing and Yin, Geng},
title = {Targeting fibroblast activation protein in rheumatoid arthritis: from molecular imaging to precision therapeutics},
journal = {Frontiers in Immunology},
year = {2025},
volume = {16},
doi = {10.3389/fimmu.2025.1616618}
}
EUVIMED